tetano
Editor, Senior Moderator
Microorganisms
. 2021 Nov 27;9(12):2446.
doi: 10.3390/microorganisms9122446.
Developing a Live Probiotic Vaccine Based on the Enterococcus faecium L3 Strain Expressing Influenza Neuraminidase
Yulia Desheva[SUP] 1 [/SUP], Galina Leontieva[SUP] 1 [/SUP], Tatiana Kramskaya[SUP] 1 [/SUP], Tatiana Gupalova[SUP] 1 [/SUP], Igor Losev[SUP] 1 [/SUP], Eugenia Kuleshevich[SUP] 1 [/SUP], Elena Bormotova[SUP] 1 [/SUP], Olga Kopteva[SUP] 1 [/SUP], Polina Kudar[SUP] 1 [/SUP], Alexander Suvorov[SUP] 1 [/SUP]
Affiliations
Abstract
Probiotic microorganisms are currently considered as a promising platform for the development of recombinant vaccines expressing foreign antigens. In this study, we generated and evaluated the live mucosal recombinant vaccine by integrating genes encoding influenza virus neuraminidase (NA) of the N2 subtype into the DNA of the probiotic strain Enterococcus faecium L3 (L3). We confirmed NA expression in the pili of L3 using immune electron microscopy. Mice were fed with a probiotic vaccine containing the NA gene (L3-NA) or pure L3. Oral administration of L3-NA caused detectable increase in virus-specific serum IgG and local IgA after the third feeding. Immunization with L3-NA increased the survival rate by 34% when the mice were infected using A(H1N1)pdm09 influenza virus after the third feeding. After S. pneumoniae post-influenza infection, the L3-NA-immunized mice were 50% more protected from lethality in comparison with L3-fed mice. Thus, a live probiotic vaccine candidate based on L3 induced the formation of systemic and local immunity and provide partial protection against complicated influenza.
Keywords: E. faecium L3; influenza neuraminidase; live mucosal vaccine; probiotic microorganism.
. 2021 Nov 27;9(12):2446.
doi: 10.3390/microorganisms9122446.
Developing a Live Probiotic Vaccine Based on the Enterococcus faecium L3 Strain Expressing Influenza Neuraminidase
Yulia Desheva[SUP] 1 [/SUP], Galina Leontieva[SUP] 1 [/SUP], Tatiana Kramskaya[SUP] 1 [/SUP], Tatiana Gupalova[SUP] 1 [/SUP], Igor Losev[SUP] 1 [/SUP], Eugenia Kuleshevich[SUP] 1 [/SUP], Elena Bormotova[SUP] 1 [/SUP], Olga Kopteva[SUP] 1 [/SUP], Polina Kudar[SUP] 1 [/SUP], Alexander Suvorov[SUP] 1 [/SUP]
Affiliations
- PMID: 34946050
- DOI: 10.3390/microorganisms9122446
Abstract
Probiotic microorganisms are currently considered as a promising platform for the development of recombinant vaccines expressing foreign antigens. In this study, we generated and evaluated the live mucosal recombinant vaccine by integrating genes encoding influenza virus neuraminidase (NA) of the N2 subtype into the DNA of the probiotic strain Enterococcus faecium L3 (L3). We confirmed NA expression in the pili of L3 using immune electron microscopy. Mice were fed with a probiotic vaccine containing the NA gene (L3-NA) or pure L3. Oral administration of L3-NA caused detectable increase in virus-specific serum IgG and local IgA after the third feeding. Immunization with L3-NA increased the survival rate by 34% when the mice were infected using A(H1N1)pdm09 influenza virus after the third feeding. After S. pneumoniae post-influenza infection, the L3-NA-immunized mice were 50% more protected from lethality in comparison with L3-fed mice. Thus, a live probiotic vaccine candidate based on L3 induced the formation of systemic and local immunity and provide partial protection against complicated influenza.
Keywords: E. faecium L3; influenza neuraminidase; live mucosal vaccine; probiotic microorganism.